Stemline Therapeutics, Inc. launched an at-the-market offering to sell up to $50 million of its common stock.
In connection with the offering, the New York-based cancer drugs developer has entered a distribution agreement with J.P. Morgan Securities LLC, Cantor Fitzgerald & Co. and Ladenburg Thalmann & Co. Inc.
